CYP2D6 and Bradycardia: The study by Nieminen T. et al. demonstrated that CYP2D6 poor metabolizers presented altered serum kinetics following administration of the aqueous formulation of timolol (0.5% aqueous timolol) with higher rates of bradycardia, although not for the hydrogel formulation (0.1% timolol hydrogel).